J. Brooks a.o.: An uncertain role for p53 gene alterations in human
prostate cancers. Cancer Res. 56/16 (1996), 3814-3822.
"This series suggests that p53 gene inactivation is rare in primary
prostatic tumors, not essential to the development of prostate cancer
metastases, and of limited use as a prognostic marker in patients
with primary or metastatic disease. Another gene or genes on
chromosome 17p may be involved in prostate cancer progression."
(From the abstract). This conclusion is based on the study of 67 prostate
tumors.

15475 Leslie Dennis/Charles Lynch/James Torner: Epidemiologic
association between prostatitis and prostate cancer.
Urology 60 (2002), 78-83.

9318 H. Harvey: A unifying hypothesis that links benign prostatic hyperplasia
and prostatic intraepithelial neoplasia with prostate cancer. Internet 1996.

Amy Hobeika/Prem Subramaniam/Howard Johnson: IFN[alpha] induces the
expression of the cyclin-dependent kinase inhibitor p21 in human prostate
cancer cells. Oncogene 13 March 1997, ...

8855 Judd Moul: The clinical relevance of oncogenes and tumor suppressor
genes in prostate cancer. Internet 1995, 16p.

15590 William Nelson/Angelo De Marzo/Theodore De Weese: The molecular
pathogenesis of prostate cancer - implications for prostate cancer
prevention. Urology 57 (suppl. 4 A) April 2001, 39-45.

8781 Elizabeth Pennisi: Homing in on a prostate cancer gene.
Science 22 November 1996, 1301.

20757 Aaron Tande/Elizabeth Platz/Aaron Folsom: The metabolic syndrome
is associated with reduced risk of prostate cancer.
Am. J. Epidemiology 164/11 (2006), 9p.